Patents by Inventor Matthew Copeland Catley

Matthew Copeland Catley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions And Methods For Inhibiting Expression Of IKK-B Gene
    Publication number: 20150240242
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the IKK-B gene, comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the IKK-B gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression or activation of the IKK-B gene using the pharmaceutical composition; and methods for inhibiting the expression of the IKK-B gene in a cell.
    Type: Application
    Filed: March 3, 2015
    Publication date: August 27, 2015
    Inventors: Antonin de Fougerolles, Andrew Sprague, Jens Harborth, Maria Gabriela Belvisi, Mark Andrew Birrell, Elizabeth Louise Hardaker, Matthew Copeland Catley
  • Compositions and methods for inhibiting expression of IKK-B gene
    Patent number: 9000143
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the IKK-B gene, comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the IKK-B gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression or activation of the IKK-B gene using the pharmaceutical composition; and methods for inhibiting the expression of the IKK-B gene in a cell.
    Type: Grant
    Filed: December 30, 2010
    Date of Patent: April 7, 2015
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Antonin de Fougerolles, Andrew Sprague, Jens Harborth, Maria Gabriela Belvisi, Mark Andrew Birrell, Elizabeth Louise Hardaker, Matthew Copeland Catley
  • Compositions And Methods For Inhibiting Expression Of IKK-B Gene
    Publication number: 20110112178
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the IKK-B gene, comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the IKK-B gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression or activation of the IKK-B gene using the pharmaceutical composition; and methods for inhibiting the expression of the IKK-B gene in a cell.
    Type: Application
    Filed: December 30, 2010
    Publication date: May 12, 2011
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Antonin de Fougerolles, Andrew Sprague, Jens Harborth, Maria Gabriela Belvisi, Mark Andrew Birrell, Elizabeth Ouise Hardaker, Matthew Copeland Catley
  • Compositions and methods for inhibiting expression of IKK-B gene
    Patent number: 7888498
    Abstract: The invention relates to a doable-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the IKK-B gene, comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the IKK-B gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases, caused by the expression or activation of the IKK-B gene using the pharmaceutical composition; and methods for inhibiting the expression of the IKK-B gene in a cell.
    Type: Grant
    Filed: May 21, 2007
    Date of Patent: February 15, 2011
    Assignees: Alnylam Pharmaceuticals, Inc., Imperial College of Science, Technology and Medicine
    Inventors: Antonin De Fougerolles, Andrew Sprague, Jens Harborth, Maria Gabriela Belvisi, Mark Andrew Birrell, Elizabeth Louise Hardaker, Matthew Copeland Catley